HIF1A and sleep apnea syndrome: Therefore, targeting cholinergic function (through cholinesterase inhibition or muscarinic agonizts)33,83 or specific HIF1α pathways (2ME2 is a current treatment for tumor angiogenesis) represents a candidate strategy for preventing AD in the SDB ‘at risk’ population—those with intermittent hypoxia.